Gossamer Bio (NASDAQ:GOSS) Stock Rating Reaffirmed by HC Wainwright

Gossamer Bio (NASDAQ:GOSS)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued to investors on Monday, Benzinga reports. They currently have a $10.00 target price on the stock.

Several other research firms have also issued reports on GOSS. Wedbush began coverage on Gossamer Bio in a report on Friday, April 5th. They set an “outperform” rating and a $4.00 target price on the stock. Piper Sandler reiterated an “overweight” rating and set a $15.00 price objective on shares of Gossamer Bio in a research note on Wednesday, March 27th. Finally, The Goldman Sachs Group decreased their price objective on shares of Gossamer Bio from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, March 6th. One analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $7.65.

Gossamer Bio Trading Down 6.3 %

NASDAQ GOSS opened at $0.73 on Monday. The stock has a market capitalization of $165.48 million, a price-to-earnings ratio of -0.53 and a beta of 1.84. Gossamer Bio has a 52 week low of $0.45 and a 52 week high of $1.88. The stock’s 50 day moving average price is $1.09 and its two-hundred day moving average price is $0.94. The company has a debt-to-equity ratio of 3.14, a quick ratio of 5.94 and a current ratio of 5.94.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings data on Tuesday, March 5th. The company reported ($0.21) EPS for the quarter, hitting analysts’ consensus estimates of ($0.21). As a group, analysts anticipate that Gossamer Bio will post -0.75 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Faheem Hasnain sold 23,172 shares of the business’s stock in a transaction dated Wednesday, March 27th. The shares were sold at an average price of $1.16, for a total value of $26,879.52. Following the completion of the sale, the chief executive officer now owns 120,293 shares of the company’s stock, valued at $139,539.88. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last quarter, insiders have sold 33,620 shares of company stock valued at $39,682. 5.00% of the stock is owned by insiders.

Institutional Investors Weigh In On Gossamer Bio

A number of large investors have recently added to or reduced their stakes in the stock. Sivia Capital Partners LLC bought a new stake in shares of Gossamer Bio during the 1st quarter valued at $29,000. SG Americas Securities LLC bought a new stake in Gossamer Bio during the first quarter worth about $34,000. Financial Advocates Investment Management bought a new position in Gossamer Bio in the 3rd quarter valued at about $61,000. Bank of New York Mellon Corp raised its position in shares of Gossamer Bio by 178.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 91,246 shares of the company’s stock valued at $76,000 after buying an additional 58,428 shares in the last quarter. Finally, Citigroup Inc. boosted its position in shares of Gossamer Bio by 9,916.9% during the 3rd quarter. Citigroup Inc. now owns 196,732 shares of the company’s stock worth $164,000 after acquiring an additional 194,768 shares in the last quarter. Institutional investors and hedge funds own 81.23% of the company’s stock.

About Gossamer Bio

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.